{"id":"W4324137014","doi":"10.1200/jco.2023.41.6_suppl.tps279","title":"TALAPRO-3: A phase 3, double-blind, randomized study of enzalutamide (ENZA) plus talazoparib (TALA) vs placebo plus ENZA in patients with DDR gene-mutated, metastatic castration-sensitive prostate cancer (mCSPC).","year":2023,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":true,"ca_institutions":"Université de Montréal","funders":"Pfizer","keywords":"Enzalutamide; Medicine; PARP inhibitor; Prostate cancer; Internal medicine; Placebo; Oncology; Cancer; Androgen receptor; Cancer research; Pathology; Poly ADP ribose polymerase; Genetics; Biology; Gene","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002026801,0.002477017,0.002697283,0.0006684067,0.0006146687,0.001284008,0.001477838,0.00224052,0.0100681],"category_scores_gemma":[0.001605143,0.0008716289,0.002104625,0.0004756897,0.001434337,0.001457308,0.0004975155,0.004011989,0.001709531],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.000958516,"about_ca_system_score_gemma":0.002144932,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.00151066,"about_ca_topic_score_gemma":0.004225374,"domain_scores_codex":[0.9994709,0.0002628543,0.0000275065,0.00008798086,0.0000422904,0.0001085077],"domain_scores_gemma":[0.9990199,0.0001938167,0.0002181404,0.0000553067,0.00006439056,0.0004483679],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.9641252,0.01570824,0.0004551727,0.0005765699,0.0007139643,0.00004466786,0.00005085667,0.0004600827,0.004948417,0.000168962,0.001500915,0.01124702],"study_design_scores_gemma":[0.933987,0.06349251,0.0008385152,0.0000155231,0.000241247,0.0000219458,0.00001505674,0.0003657833,0.000351772,0.0001383449,0.0005166337,0.00001569026],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9672369,0.004169379,0.001364559,0.001656848,0.001006448,0.0165326,0.00365285,0.0004865588,0.003893788],"genre_scores_gemma":[0.963039,0.002883787,0.003570581,0.003584546,0.000628708,0.01601149,0.002934915,0.00007655904,0.007270411],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.0100681,"threshold_uncertainty_score":0.03368109,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.1480523136560727,"score_gpt":0.4902022351030057,"score_spread":0.342149921446933,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}